17872-58-1

Basic information

• Product Name: 2,2-BIS-(ACETOXYMETHYL)PROPIONIC ACID
• Synonyms: 2,2-BIS-(ACETOXYMETHYL)PROPIONIC ACID
• CAS NO: 17872-58-1
• Molecular Formula: C₉H₁₄O₆
• Molecular Weight: 218.2
• Mol File: 17872-58-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,2-BIS-(ACETOXYMETHYL)PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-BIS-(ACETOXYMETHYL)PROPIONIC ACID(17872-58-1)
• EPA Substance Registry System: 2,2-BIS-(ACETOXYMETHYL)PROPIONIC ACID(17872-58-1)

Safety Data

• Hazardous Substances Data: 17872-58-1(Hazardous Substances Data)

Usage

General Description

2,2-BIS-(ACETOXYMETHYL)PROPIONIC ACID is a chemical compound used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is a propionic acid derivative with two acetoxy substituents. 2,2-BIS-(ACETOXYMETHYL)PROPIONIC ACID is a white to off-white crystalline powder and is soluble in organic solvents. It is commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals due to its versatile reactivity and functional groups. Additionally, it is used as a chemical reagent in organic synthesis and as a precursor for the synthesis of more complex organic compounds.

Upstream product

• 4767-03-7 2,2-bis(hydroxymethyl)propionic acid 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 

Downstream Products

• 17872-59-2 2,2-bis(acetoxymethyl)propanoic acid chloride 
• 1303947-84-3 KNI-10858 
• 179388-74-0 3-(3-Acetoxy-2-acetoxymethyl-2-methyl-propionyloxy)-2-(3-acetoxy-2-acetoxymethyl-2-methyl-propionyloxymethyl)-2-methyl-propionic acid benzyl ester 
• 179388-87-5 C₅₈H₈₀O₃₀ 

Relevant articles and documents

Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles

The human T cell leukemia/lymphotropic virus type 1 (HTLV-I) is clinically associated with adult T cell leukemia/lymphoma, HTLV-I associated myelopathy/tropical spastic paraparesis, and a number of other chronic inflammatory diseases. To stop the replication of the virus, we developed highly potent tetrapeptidic HTLV-I protease inhibitors. In a recent X-ray crystallography study, several of our inhibitors could not form co-crystal complexes with the protease due to their high hydrophobicity. In the current study, we designed, synthesized and evaluated the HTLV-I protease inhibition potency of compounds with hydrophilic end-capping moieties with the aim of improving pharmaceutic and pharmacokinetic properties.

Dye derived from a pyrazolotriazole

A method of retouching a dye image comprises selective removal with an aqueous acidic organic solvent solution, as described in the application, of a portion of a dye image from an exposed and processed photographic silver halide element comprising a support bearing a dye image from a dye-forming coupler and a primary amine photographic color developing agent, wherein the dye-forming coupler: (a) contains so ionizable group that is retained as part of a dye formed upon oxidative coupling, (b) has a structure such that the Log P of the coupler is greater than 4 and is derived from a four-equivalent coupler that has a Log P less than 8, and (c) has a coupling reactivity that enables formation of maximum image density of at least 0.6. The method comprises the step of contacting the dye image with an aqueous acidic organic solvent solution, as described in the application, for a time and at a temperature sufficient to selectively dissolve and remove a portion of the dye image from the photographic element. A new photographic element designed for such retouching comprises new pyrazolotriazole couplers as described in the application.